Genetic Rodent Models of Huntington Disease

  • J. Stricker-Shaver
  • A. Novati
  • L. Yu-Taeger
  • H. P. Nguyen
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 1049)


The monogenic nature of Huntington disease (HD) has led to the development of a spectrum of useful genetically modified models. In particular, rodents have pioneered as the first HD model being generated and have since been the most widely used animal model for HD in both basic research and preclinical therapeutic studies. Based on the generation strategies, these rodent models can be classified into 3 major groups, the transgenic fragment models, the transgenic full-length models and the knock-in models. These models display a range of HD-like characteristics which resemble the clinical symptoms of HD patients. Their applications in research are thus regarded as an invaluable approach to speeding up the unraveling of the underlying pathological mechanisms of HD and for finding a disease-modifying treatment for this devastating disease. In this chapter, the similarities and differences of the most commonly used rodent HD models and their relevance to human HD will be compared and discussed. This also serves to guide the selection of an appropriate rodent HD model according to the nature of investigation.


Huntington disease Transgenic Knock-in Mouse Rat 


  1. 1.
    The Huntington’s Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell 72:971–983CrossRefGoogle Scholar
  2. 2.
    Pouladi MA, Morton AJ, Hayden MR (2013) Choosing an animal model for the study of Huntington’s disease. Nat Rev Neurosci 14:708–721PubMedCrossRefGoogle Scholar
  3. 3.
    Chang R, Liu X, Li S, Li XJ (2015) Transgenic animal models for study of the pathogenesis of Huntington’s disease and therapy. Drug Des Devel Ther 9:2179–2188PubMedPubMedCentralGoogle Scholar
  4. 4.
    Crook ZR, Housman D (2011) Huntington’s disease: can mice lead the way to treatment? Neuron 69:423–435PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    Li JY, Popovic N, Brundin P (2005) The use of the R6 transgenic mouse models of Huntington’s disease in attempts to develop novel therapeutic strategies. NeuroRx 2:447–464PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Switonski PM, Szlachcic WJ, Gabka A, Krzyzosiak WJ, Figiel M (2012) Mouse models of polyglutamine diseases in therapeutic approaches: review and data table Part II. Mol Neurobiol 46:430–466PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Heng MY, Duong DK, Albin RL, Tallaksen-Greene SJ, Hunter JM, Lesort MJ, Osmand A, Paulson HL, Detloff PJ (2010) Early autophagic response in a novel knock-in model of Huntington disease. Hum Mol Genet 19:3702–3720PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Jucker M (2010) The benefits and limitations of animal models for translational research in neurodegenerative diseases. Nat Med 16:1210–1214PubMedCrossRefGoogle Scholar
  9. 9.
    Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, Lawton M, Trottier Y, Lehrach H, Davies SW, Bates GP (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87:493–506PubMedCrossRefGoogle Scholar
  10. 10.
    Davies SW, Turmaine M, Cozens BA, DiFiglia M, Sharp AH, Ross CA, Scherzinger E, Wanker EE, Mangiarini L, Bates GP (1997) Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90:537–548PubMedCrossRefGoogle Scholar
  11. 11.
    Mangiarini L, Sathasivam K, Mahal A, Mott R, Seller M, Bates GP (1997) Instability of highly expanded CAG repeats in mice transgenic for the Huntington’s disease mutation. Nat Genet 15:197–200PubMedCrossRefGoogle Scholar
  12. 12.
    Schilling G, Becher MW, Sharp AH, Jinnah HA, Duan K, Kotzuk JA, Slunt HH, Ratovitski T, Cooper JK, Jenkins NA, Copeland NG, Price DL, Ross CA, Borchelt DR (1999) Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum Mol Genet 8:397–407PubMedCrossRefGoogle Scholar
  13. 13.
    Graham RK, Deng Y, Slow EJ, Haigh B, Bissada N, Lu G, Pearson J, Shehadeh J, Bertram L, Murphy Z, Warby SC, Doty CN, Roy S, Wellington CL, Leavitt BR, Raymond LA, Nicholson DW, Hayden MR (2006) Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell 125:1179–1191PubMedCrossRefGoogle Scholar
  14. 14.
    Tebbenkamp AT, Green C, Xu G, Denovan-Wright EM, Rising AC, Fromholt SE, Brown HH, Swing D, Mandel RJ, Tessarollo L, Borchelt DR (2011) Transgenic mice expressing caspase-6-derived N-terminal fragments of mutant huntingtin develop neurologic abnormalities with predominant cytoplasmic inclusion pathology composed largely of a smaller proteolytic derivative. Hum Mol Genet 20:2770–2782PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Carter RJ, Lione LA, Humby T, Mangiarini L, Mahal A, Bates GP, Dunnett SB, Morton AJ (1999) Characterization of progressive motor deficits in mice transgenic for the human Huntington’s disease mutation. J Neurosci 19:3248–3257PubMedCrossRefGoogle Scholar
  16. 16.
    Stack EC, Kubilus JK, Smith K, Cormier K, Del Signore SJ, Guelin E, Ryu H, Hersch SM, Ferrante RJ (2005) Chronology of behavioral symptoms and neuropathological sequela in R6/2 Huntington’s disease transgenic mice. J Comp Neurol 490:354–370PubMedCrossRefGoogle Scholar
  17. 17.
    Sathasivam K, Hobbs C, Mangiarini L, Mahal A, Turmaine M, Doherty P, Davies SW, Bates GP (1999) Transgenic models of Huntington’s disease. Philos Trans R Soc Lond B Biol Sci 354:963–969PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Young D, Mayer F, Vidotto N, Schweizer T, Berth R, Abramowski D, Shimshek DR, van der Putten PH, Schmid P (2013) Mutant huntingtin gene-dose impacts on aggregate deposition, DARPP32 expression and neuroinflammation in HdhQ150 mice. PLoS ONE 8:e75108PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Schilling G, Savonenko AV, Klevytska A, Morton JL, Tucker SM, Poirier M, Gale A, Chan N, Gonzales V, Slunt HH, Coonfield ML, Jenkins NA, Copeland NG, Ross CA, Borchelt DR (2004) Nuclear-targeting of mutant huntingtin fragments produces Huntington’s disease-like phenotypes in transgenic mice. Hum Mol Genet 13:1599–1610PubMedCrossRefGoogle Scholar
  20. 20.
    Waldron-Roby E, Ratovitski T, Wang X, Jiang M, Watkin E, Arbez N, Graham RK, Hayden MR, Hou Z, Mori S, Swing D, Pletnikov M, Duan W, Tessarollo L, Ross CA (2012) Transgenic mouse model expressing the caspase 6 fragment of mutant huntingtin. J Neurosci 32:183–193PubMedCrossRefGoogle Scholar
  21. 21.
    Hickey MA, Gallant K, Gross GG, Levine MS, Chesselet MF (2005) Early behavioral deficits in R6/2 mice suitable for use in preclinical drug testing. Neurobiol Dis 20:1–11PubMedCrossRefGoogle Scholar
  22. 22.
    Paulsen JS (2011) Cognitive impairment in Huntington disease: diagnosis and treatment. Curr Neurol Neurosci Rep 11:474–483PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Snowden JS, Craufurd D, Thompson J, Neary D (2002) Psychomotor, executive, and memory function in preclinical Huntington’s disease. J Clin Exp Neuropsychol 24:133–145PubMedCrossRefGoogle Scholar
  24. 24.
    Lione LA, Carter RJ, Hunt MJ, Bates GP, Morton AJ, Dunnett SB (1999) Selective discrimination learning impairments in mice expressing the human Huntington’s disease mutation. J Neurosci 19:10428–10437PubMedCrossRefGoogle Scholar
  25. 25.
    Bolivar VJ, Manley K, Messer A (2003) Exploratory activity and fear conditioning abnormalities develop early in R6/2 Huntington’s disease transgenic mice. Behav Neurosci 117:1233–1242PubMedCrossRefGoogle Scholar
  26. 26.
    Morton AJ, Skillings E, Bussey TJ, Saksida LM (2006) Measuring cognitive deficits in disabled mice using an automated interactive touchscreen system. Nat Methods 3:767PubMedCrossRefGoogle Scholar
  27. 27.
    Ramaswamy S, McBride JL, Kordower JH (2007) Animal models of Huntington’s disease. ILAR J 48:356–373PubMedCrossRefGoogle Scholar
  28. 28.
    Chiu CT, Liu G, Leeds P, Chuang DM (2011) Combined treatment with the mood stabilizers lithium and valproate produces multiple beneficial effects in transgenic mouse models of Huntington’s disease. Neuropsychopharmacology 36:2406–2421PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    Epping EA, Paulsen JS (2011) Depression in the early stages of Huntington disease. Neurodegener Dis Manag 1:407–414PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Pla P, Orvoen S, Saudou F, David DJ, Humbert S (2014) Mood disorders in Huntington’s disease: from behavior to cellular and molecular mechanisms. Front Behav Neurosci 8:135PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    Lunkes A, Lindenberg KS, Ben-Haiem L, Weber C, Devys D, Landwehrmeyer GB, Mandel JL, Trottier Y (2002) Proteases acting on mutant huntingtin generate cleaved products that differentially build up cytoplasmic and nuclear inclusions. Mol Cell 10:259–269PubMedCrossRefGoogle Scholar
  32. 32.
    Schilling G, Klevytska A, Tebbenkamp AT, Juenemann K, Cooper J, Gonzales V, Slunt H, Poirer M, Ross CA, Borchelt DR (2007) Characterization of huntingtin pathologic fragments in human Huntington disease, transgenic mice, and cell models. J Neuropathol Exp Neurol 66:313–320PubMedCrossRefGoogle Scholar
  33. 33.
    Vonsattel JP, DiFiglia M (1998) Huntington disease. J Neuropathol Exp Neurol 57:369–384PubMedCrossRefGoogle Scholar
  34. 34.
    Schilling G, Jinnah HA, Gonzales V, Coonfield ML, Kim Y, Wood JD, Price DL, Li XJ, Jenkins N, Copeland N, Moran T, Ross CA, Borchelt DR (2001) Distinct behavioral and neuropathological abnormalities in transgenic mouse models of HD and DRPLA. Neurobiol Dis 8:405–418PubMedCrossRefGoogle Scholar
  35. 35.
    Slow EJ, van Raamsdonk J, Rogers D, Coleman SH, Graham RK, Deng Y, Oh R, Bissada N, Hossain SM, Yang YZ, Li XJ, Simpson EM, Gutekunst CA, Leavitt BR, Hayden MR (2003) Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum Mol Genet 12:1555–1567PubMedCrossRefGoogle Scholar
  36. 36.
    Gray M, Shirasaki DI, Cepeda C, Andre VM, Wilburn B, Lu XH, Tao J, Yamazaki I, Li SH, Sun YE, Li XJ, Levine MS, Yang XW (2008) Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J Neurosci 28:6182–6195PubMedPubMedCentralCrossRefGoogle Scholar
  37. 37.
    Hodgson JG, Agopyan N, Gutekunst CA, Leavitt BR, LePiane F, Singaraja R, Smith DJ, Bissada N, McCutcheon K, Nasir J, Jamot L, Li XJ, Stevens ME, Rosemond E, Roder JC, Phillips AG, Rubin EM, Hersch SM, Hayden MR (1999) A YAC mouse model for Huntington’s disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron 23:181–192PubMedCrossRefGoogle Scholar
  38. 38.
    Wegrzynowicz M, Bichell TJ, Soares BD, Loth MK, McGlothan JS, Mori S, Alikhan FS, Hua K, Coughlin JM, Holt HK, Jetter CS, Pomper MG, Osmand AP, Guilarte TR, Bowman AB (2015) Novel BAC mouse model of Huntington’s disease with 225 CAG repeats exhibits an early widespread and stable degenerative phenotype. J Huntingtons Dis 4:17–36PubMedPubMedCentralGoogle Scholar
  39. 39.
    Van Raamsdonk JM, Pearson J, Rogers DA, Bissada N, Vogl AW, Hayden MR, Leavitt BR (2005) Loss of wild-type huntingtin influences motor dysfunction and survival in the YAC128 mouse model of Huntington disease. Hum Mol Genet 14:1379–1392PubMedCrossRefGoogle Scholar
  40. 40.
    Aziz NA, Van Der Burg JM, Landwehrmeyer GB, Brundin P, Stijnen T, Group ES, Roos RAC (2008) Weight loss in Huntington disease increases with higher CAG repeat number. Neurology 71(19):1506–1513PubMedCrossRefGoogle Scholar
  41. 41.
    Pouladi MA, Stanek LM, Xie Y, Franciosi S, Southwell AL, Deng Y, Butland S, Zhang W, Cheng SH, Shihabuddin LS, Hayden MR (2012) Marked differences in neurochemistry and aggregates despite similar behavioural and neuropathological features of Huntington disease in the full-length BACHD and YAC128 mice. Hum Mol Genet 21:2219–2232PubMedCrossRefGoogle Scholar
  42. 42.
    Baldo B, Cheong RY, Petersen A (2014) Effects of deletion of mutant huntingtin in steroidogenic factor 1 neurons on the psychiatric and metabolic phenotype in the BACHD mouse model of Huntington disease. PLoS ONE 9:e107691PubMedPubMedCentralCrossRefGoogle Scholar
  43. 43.
    Van Raamsdonk JM, Gibson WT, Pearson J, Murphy Z, Lu G, Leavitt BR, Hayden MR (2006) Body weight is modulated by levels of full-length huntingtin. Hum Mol Genet 15:1513–1523PubMedCrossRefGoogle Scholar
  44. 44.
    Southwell AL, Franciosi S, Villanueva EB, Xie Y, Winter LA, Veeraraghavan J, Jonason A, Felczak B, Zhang W, Kovalik V, Waltl S, Hall G, Pouladi MA, Smith ES, Bowers WJ, Zauderer M, Hayden MR (2015) Anti-semaphorin 4D immunotherapy ameliorates neuropathology and some cognitive impairment in the YAC128 mouse model of Huntington disease. Neurobiol Dis 76:46–56PubMedCrossRefGoogle Scholar
  45. 45.
    Van Raamsdonk JM, Murphy Z, Selva DM, Hamidizadeh R, Pearson J, Petersen A, Bjorkqvist M, Muir C, Mackenzie IR, Hammond GL, Vogl AW, Hayden MR, Leavitt BR (2007) Testicular degeneration in Huntington disease. Neurobiol Dis 26:512–520PubMedCrossRefGoogle Scholar
  46. 46.
    Hult S, Soylu R, Bjorklund T, Belgardt BF, Mauer J, Bruning JC, Kirik D, Petersen A (2011) Mutant huntingtin causes metabolic imbalance by disruption of hypothalamic neurocircuits. Cell Metab 13:428–439PubMedCrossRefGoogle Scholar
  47. 47.
    Lalic NM, Maric J, Svetel M, Jotic A, Stefanova E, Lalic K, Dragasevic N, Milicic T, Lukic L, Kostic VS (2008) Glucose homeostasis in Huntington disease: abnormalities in insulin sensitivity and early-phase insulin secretion. Arch Neurol 65:476–480PubMedCrossRefGoogle Scholar
  48. 48.
    Pouladi MA, Xie Y, Skotte NH, Ehrnhoefer DE, Graham RK, Kim JE, Bissada N, Yang XW, Paganetti P, Friedlander RM, Leavitt BR, Hayden MR (2010) Full-length huntingtin levels modulate body weight by influencing insulin-like growth factor 1 expression. Hum Mol Genet 19:1528–1538PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Aziz NA, Pijl H, Frolich M, van der Graaf AW, Roelfsema F, Roos RA (2009) Increased hypothalamic-pituitary-adrenal axis activity in Huntington’s disease. J Clin Endocrinol Metab 94:1223–1228PubMedCrossRefGoogle Scholar
  50. 50.
    Markianos M, Panas M, Kalfakis N, Vassilopoulos D (2005) Plasma testosterone in male patients with Huntington’s disease: relations to severity of illness and dementia. Ann Neurol 57:520–525PubMedCrossRefGoogle Scholar
  51. 51.
    Menalled L, El-Khodor BF, Patry M, Suarez-Farinas M, Orenstein SJ, Zahasky B, Leahy C, Wheeler V, Yang XW, MacDonald M, Morton AJ, Bates G, Leeds J, Park L, Howland D, Signer E, Tobin A, Brunner D (2009) Systematic behavioral evaluation of Huntington’s disease transgenic and knock-in mouse models. Neurobiol Dis 35:319–336PubMedPubMedCentralCrossRefGoogle Scholar
  52. 52.
    Chen X, Wu J, Lvovskaya S, Herndon E, Supnet C, Bezprozvanny I (2011) Dantrolene is neuroprotective in Huntington’s disease transgenic mouse model. Mol Neurodegener 6:81PubMedPubMedCentralCrossRefGoogle Scholar
  53. 53.
    Mantovani S, Gordon R, Li R, Christie DC, Kumar V, Woodruff TM (2016) Motor deficits associated with Huntington’s disease occur in the absence of striatal degeneration in BACHD transgenic mice. Hum Mol Genet 25:1780–1791PubMedCrossRefGoogle Scholar
  54. 54.
    Lichter DG, Hershey LA (2010) Before chorea: pre-Huntington mild cognitive impairment. Neurology 75:490–491PubMedCrossRefGoogle Scholar
  55. 55.
    Giralt A, Saavedra A, Alberch J, Perez-Navarro E (2012) Cognitive dysfunction in Huntington’s disease: humans, mouse models and molecular mechanisms. J Huntingtons Dis 1:155–173PubMedGoogle Scholar
  56. 56.
    Doria JG, Silva FR, de Souza JM, Vieira LB, Carvalho TG, Reis HJ, Pereira GS, Dobransky T, Ribeiro FM (2013) Metabotropic glutamate receptor 5 positive allosteric modulators are neuroprotective in a mouse model of Huntington’s disease. Br J Pharmacol 169:909–921PubMedPubMedCentralCrossRefGoogle Scholar
  57. 57.
    Southwell AL, Ko J, Patterson PH (2009) Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington’s disease. J Neurosci 29:13589–13602PubMedPubMedCentralCrossRefGoogle Scholar
  58. 58.
    Van Raamsdonk JM, Pearson J, Slow EJ, Hossain SM, Leavitt BR, Hayden MR (2005) Cognitive dysfunction precedes neuropathology and motor abnormalities in the YAC128 mouse model of Huntington’s disease. J Neurosci 25:4169–4180PubMedCrossRefGoogle Scholar
  59. 59.
    Abada YS, Schreiber R, Ellenbroek B (2013) Motor, emotional and cognitive deficits in adult BACHD mice: a model for Huntington’s disease. Behav Brain Res 238:243–251PubMedCrossRefGoogle Scholar
  60. 60.
    Aharony I, Ehrnhoefer DE, Shruster A, Qiu X, Franciosi S, Hayden MR, Offen D (2015) A Huntingtin-based peptide inhibitor of caspase-6 provides protection from mutant Huntingtin-induced motor and behavioral deficits. Hum Mol Genet 24:2604–2614PubMedPubMedCentralCrossRefGoogle Scholar
  61. 61.
    Brooks S, Higgs G, Janghra N, Jones L, Dunnett SB (2012) Longitudinal analysis of the behavioural phenotype in YAC128 (C57BL/6 J) Huntington’s disease transgenic mice. Brain Res Bull 88:113–120PubMedCrossRefGoogle Scholar
  62. 62.
    Brooks SP, Janghra N, Higgs GV, Bayram-Weston Z, Heuer A, Jones L, Dunnett SB (2012) Selective cognitive impairment in the YAC128 Huntington’s disease mouse. Brain Res Bull 88:121–129PubMedCrossRefGoogle Scholar
  63. 63.
    Hult Lundh S, Nilsson N, Soylu R, Kirik D, Petersen A (2013) Hypothalamic expression of mutant huntingtin contributes to the development of depressive-like behavior in the BAC transgenic mouse model of Huntington’s disease. Hum Mol Genet 22:3485–3497PubMedCrossRefGoogle Scholar
  64. 64.
    Pouladi MA, Graham RK, Karasinska JM, Xie Y, Santos RD, Petersen A, Hayden MR (2009) Prevention of depressive behaviour in the YAC128 mouse model of Huntington disease by mutation at residue 586 of huntingtin. Brain 132:919–932PubMedCrossRefGoogle Scholar
  65. 65.
    DiFiglia M, Sapp E, Chase KO, Davies SW, Bates GP, Vonsattel JP, Aronin N (1997) Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277:1990–1993PubMedCrossRefGoogle Scholar
  66. 66.
    Carroll JB, Lerch JP, Franciosi S, Spreeuw A, Bissada N, Henkelman RM, Hayden MR (2011) Natural history of disease in the YAC128 mouse reveals a discrete signature of pathology in Huntington disease. Neurobiol Dis 43:257–265PubMedCrossRefGoogle Scholar
  67. 67.
    Teo RT, Hong X, Yu-Taeger L, Huang Y, Tan LJ, Xie Y, To XV, Guo L, Rajendran R, Novati A, Calaminus C, Riess O, Hayden MR, Nguyen HP, Chuang KH, Pouladi MA (2016) Structural and molecular myelination deficits occur prior to neuronal loss in the YAC128 and BACHD models of Huntington disease. Hum Mol Genet 25:2621–2632PubMedPubMedCentralGoogle Scholar
  68. 68.
    Gatto RG, Chu Y, Ye AQ, Price SD, Tavassoli E, Buenaventura A, Brady ST, Magin RL, Kordower JH, Morfini GA (2015) Analysis of YFP(J16)-R6/2 reporter mice and postmortem brains reveals early pathology and increased vulnerability of callosal axons in Huntington’s disease. Hum Mol Genet 24:5285–5298PubMedPubMedCentralCrossRefGoogle Scholar
  69. 69.
    Jin J, Peng Q, Hou Z, Jiang M, Wang X, Langseth AJ, Tao M, Barker PB, Mori S, Bergles DE, Ross CA, Detloff PJ, Zhang J, Duan W (2015) Early white matter abnormalities, progressive brain pathology and motor deficits in a novel knock-in mouse model of Huntington’s disease. Hum Mol Genet 24:2508–2527PubMedPubMedCentralCrossRefGoogle Scholar
  70. 70.
    Rosas HD, Tuch DS, Hevelone ND, Zaleta AK, Vangel M, Hersch SM, Salat DH (2006) Diffusion tensor imaging in presymptomatic and early Huntington’s disease: Selective white matter pathology and its relationship to clinical measures. Mov Disord 21:1317–1325PubMedCrossRefGoogle Scholar
  71. 71.
    Heng MY, Tallaksen-Greene SJ, Detloff PJ, Albin RL (2007) Longitudinal evaluation of the Hdh(CAG)150 knock-in murine model of Huntington’s disease. J Neurosci 27:8989–8998PubMedCrossRefGoogle Scholar
  72. 72.
    Wheeler VC, Auerbach W, White JK, Srinidhi J, Auerbach A, Ryan A, Duyao MP, Vrbanac V, Weaver M, Gusella JF, Joyner AL, MacDonald ME (1999) Length-dependent gametic CAG repeat instability in the Huntington’s disease knock-in mouse. Hum Mol Genet 8:115–122PubMedCrossRefGoogle Scholar
  73. 73.
    Menalled LB, Sison JD, Dragatsis I, Zeitlin S, Chesselet MF (2003) Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington’s disease with 140 CAG repeats. J Comp Neurol 465:11–26PubMedCrossRefGoogle Scholar
  74. 74.
    Menalled LB, Kudwa AE, Miller S, Fitzpatrick J, Watson-Johnson J, Keating N, Ruiz M, Mushlin R, Alosio W, McConnell K, Connor D, Murphy C, Oakeshott S, Kwan M, Beltran J, Ghavami A, Brunner D, Park LC, Ramboz S, Howland D (2012) Comprehensive behavioral and molecular characterization of a new knock-in mouse model of Huntington’s disease: zQ175. PLoS ONE 7:e49838PubMedPubMedCentralCrossRefGoogle Scholar
  75. 75.
    Lin CH, Tallaksen-Greene S, Chien WM, Cearley JA, Jackson WS, Crouse AB, Ren S, Li XJ, Albin RL, Detloff PJ (2001) Neurological abnormalities in a knock-in mouse model of Huntington’s disease. Hum Mol Genet 10:137–144PubMedCrossRefGoogle Scholar
  76. 76.
    Holter SM et al (2013) A broad phenotypic screen identifies novel phenotypes driven by a single mutant allele in Huntington’s disease CAG knock-in mice. PLoS ONE 8:e80923PubMedPubMedCentralCrossRefGoogle Scholar
  77. 77.
    Phan J, Hickey MA, Zhang P, Chesselet MF, Reue K (2009) Adipose tissue dysfunction tracks disease progression in two Huntington’s disease mouse models. Hum Mol Genet 18:1006–1016PubMedPubMedCentralCrossRefGoogle Scholar
  78. 78.
    Wheeler VC, White JK, Gutekunst CA, Vrbanac V, Weaver M, Li XJ, Li SH, Yi H, Vonsattel JP, Gusella JF, Hersch S, Auerbach W, Joyner AL, MacDonald ME (2000) Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice. Hum Mol Genet 9:503–513PubMedCrossRefGoogle Scholar
  79. 79.
    Hickey MA, Kosmalska A, Enayati J, Cohen R, Zeitlin S, Levine MS, Chesselet MF (2008) Extensive early motor and non-motor behavioral deficits are followed by striatal neuronal loss in knock-in Huntington’s disease mice. Neuroscience 157:280–295PubMedPubMedCentralCrossRefGoogle Scholar
  80. 80.
    Lawrence AD, Sahakian BJ, Hodges JR, Rosser AE, Lange KW, Robbins TW (1996) Executive and mnemonic functions in early Huntington’s disease. Brain 119:1633–1645PubMedCrossRefGoogle Scholar
  81. 81.
    Curtin PC, Farrar AM, Oakeshott S, Sutphen J, Berger J, Mazzella M, Cox K, He D, Alosio W, Park LC, Howland D, Brunner D (2015) Cognitive training at a young age attenuates deficits in the zQ175 mouse model of HD. Front Behav Neurosci 9:361PubMedGoogle Scholar
  82. 82.
    Heikkinen T, Lehtimaki K, Vartiainen N, Puolivali J, Hendricks SJ, Glaser JR, Bradaia A, Wadel K, Touller C, Kontkanen O, Yrjanheikki JM, Buisson B, Howland D, Beaumont V, Munoz-Sanjuan I, Park LC (2012) Characterization of neurophysiological and behavioral changes, MRI brain volumetry and 1H MRS in zQ175 knock-in mouse model of Huntington’s disease. PLoS ONE 7:e50717PubMedPubMedCentralCrossRefGoogle Scholar
  83. 83.
    Smith GA, Rocha EM, McLean JR, Hayes MA, Izen SC, Isacson O, Hallett PJ (2014) Progressive axonal transport and synaptic protein changes correlate with behavioral and neuropathological abnormalities in the heterozygous Q175 KI mouse model of Huntington’s disease. Hum Mol Genet 23:4510–4527PubMedCrossRefGoogle Scholar
  84. 84.
    Brooks S, Higgs G, Jones L, Dunnett SB (2012) Longitudinal analysis of the behavioural phenotype in Hdh(CAG)150 Huntington’s disease knock-in mice. Brain Res Bull 88:182–188PubMedCrossRefGoogle Scholar
  85. 85.
    Orvoen S, Pla P, Gardier AM, Saudou F, David DJ (2012) Huntington’s disease knock-in male mice show specific anxiety-like behaviour and altered neuronal maturation. Neurosci Lett 507:127–132PubMedCrossRefGoogle Scholar
  86. 86.
    Ciamei A, Detloff PJ, Morton AJ (2015) Progression of behavioural despair in R6/2 and Hdh knock-in mouse models recapitulates depression in Huntington’s disease. Behav Brain Res 291:140–146PubMedCrossRefGoogle Scholar
  87. 87.
    Wheeler VC, Gutekunst CA, Vrbanac V, Lebel LA, Schilling G, Hersch S, Friedlander RM, Gusella JF, Vonsattel JP, Borchelt DR, MacDonald ME (2002) Early phenotypes that presage late-onset neurodegenerative disease allow testing of modifiers in Hdh CAG knock-in mice. Hum Mol Genet 11:633–640PubMedCrossRefGoogle Scholar
  88. 88.
    Lerner RP, Trejo Martinez Ldel C, Zhu C, Chesselet MF, Hickey MA (2012) Striatal atrophy and dendritic alterations in a knock-in mouse model of Huntington’s disease. Brain Res Bull 87:571–578PubMedPubMedCentralCrossRefGoogle Scholar
  89. 89.
    Cummings DM, Cepeda C, Levine MS (2010) Alterations in striatal synaptic transmission are consistent across genetic mouse models of Huntington’s disease. ASN Neuro 2:e00036PubMedPubMedCentralCrossRefGoogle Scholar
  90. 90.
    Yu ZX, Li SH, Evans J, Pillarisetti A, Li H, Li XJ (2003) Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington’s disease. J Neurosci 23:2193–2202PubMedGoogle Scholar
  91. 91.
    Baldo B, Paganetti P, Grueninger S, Marcellin D, Kaltenbach LS, Lo DC, Semmelroth M, Zivanovic A, Abramowski D, Smith D, Lotz GP, Bates GP, Weiss A (2012) TR-FRET-based duplex immunoassay reveals an inverse correlation of soluble and aggregated mutant huntingtin in huntington’s disease. Chem Biol 19:264–275PubMedCrossRefGoogle Scholar
  92. 92.
    Marcellin D, Abramowski D, Young D, Richter J, Weiss A, Marcel A, Maassen J, Kauffmann M, Bibel M, Shimshek DR, Faull RL, Bates GP, Kuhn RR, Van der Putten PH, Schmid P, Lotz GP (2012) Fragments of HdhQ150 mutant huntingtin form a soluble oligomer pool that declines with aggregate deposition upon aging. PLoS ONE 7:e44457PubMedPubMedCentralCrossRefGoogle Scholar
  93. 93.
    Squitieri F, Gellera C, Cannella M, Mariotti C, Cislaghi G, Rubinsztein DC, Almqvist EW, Turner D, Bachoud-Levi AC, Simpson SA, Delatycki M, Maglione V, Hayden MR, Donato SD (2003) Homozygosity for CAG mutation in Huntington disease is associated with a more severe clinical course. Brain 126:946–955PubMedCrossRefGoogle Scholar
  94. 94.
    Heng MY, Detloff PJ, Paulson HL, Albin RL (2010) Early alterations of autophagy in Huntington disease-like mice. Autophagy 6:1206–1208PubMedPubMedCentralCrossRefGoogle Scholar
  95. 95.
    Dougherty SE, Reeves JL, Lesort M, Detloff PJ, Cowell RM (2013) Purkinje cell dysfunction and loss in a knock-in mouse model of Huntington disease. Exp Neurol 240:96–102PubMedCrossRefGoogle Scholar
  96. 96.
    Ehrlich ME (2012) Huntington’s disease and the striatal medium spiny neuron: cell-autonomous and non-cell-autonomous mechanisms of disease. Neurotherapeutics 9:270–284PubMedPubMedCentralCrossRefGoogle Scholar
  97. 97.
    Zuccato C, Cattaneo E (2007) Role of brain-derived neurotrophic factor in Huntington’s disease. Prog Neurobiol 81:294–330PubMedCrossRefGoogle Scholar
  98. 98.
    Niccolini F, Politis M (2014) Neuroimaging in Huntington’s disease. World J Radiol 6:301–312PubMedPubMedCentralCrossRefGoogle Scholar
  99. 99.
    von Horsten S et al (2003) Transgenic rat model of Huntington’s disease. Hum Mol Genet 12:617–624CrossRefGoogle Scholar
  100. 100.
    Kirch RD, Meyer PT, Geisler S, Braun F, Gehrig S, Langen KJ, von Horsten S, Nikkhah G, Cassel JC, Dobrossy MD (2013) Early deficits in declarative and procedural memory dependent behavioral function in a transgenic rat model of Huntington’s disease. Behav Brain Res 239:15–26PubMedCrossRefGoogle Scholar
  101. 101.
    Nguyen HP, Kobbe P, Rahne H, Worpel T, Jager B, Stephan M, Pabst R, Holzmann C, Riess O, Korr H, Kantor O, Petrasch-Parwez E, Wetzel R, Osmand A, von Horsten S (2006) Behavioral abnormalities precede neuropathological markers in rats transgenic for Huntington’s disease. Hum Mol Genet 15:3177–3194PubMedCrossRefGoogle Scholar
  102. 102.
    Petrasch-Parwez E, Nguyen HP, Lobbecke-Schumacher M, Habbes HW, Wieczorek S, Riess O, Andres KH, Dermietzel R, Von Horsten S (2007) Cellular and subcellular localization of Huntingtin [corrected] aggregates in the brain of a rat transgenic for Huntington disease. J Comp Neurol 501:716–730PubMedCrossRefGoogle Scholar
  103. 103.
    Kantor O, Temel Y, Holzmann C, Raber K, Nguyen HP, Cao C, Turkoglu HO, Rutten BP, Visser-Vandewalle V, Steinbusch HW, Blokland A, Korr H, Riess O, von Horsten S, Schmitz C (2006) Selective striatal neuron loss and alterations in behavior correlate with impaired striatal function in Huntington’s disease transgenic rats. Neurobiol Dis 22:538–547PubMedCrossRefGoogle Scholar
  104. 104.
    Winkler C, Gil JM, Araujo IM, Riess O, Skripuletz T, von Horsten S, Petersen A (2006) Normal sensitivity to excitotoxicity in a transgenic Huntington’s disease rat. Brain Res Bull 69:306–310PubMedCrossRefGoogle Scholar
  105. 105.
    Fink KD, Rossignol J, Crane AT, Davis KK, Bavar AM, Dekorver NW, Lowrance SA, Reilly MP, Sandstrom MI, von Horsten S, Lescaudron L, Dunbar GL (2012) Early cognitive dysfunction in the HD 51 CAG transgenic rat model of Huntington’s disease. Behav Neurosci 126:479–487PubMedCrossRefGoogle Scholar
  106. 106.
    Casteels C, Vandeputte C, Rangarajan JR, Dresselaers T, Riess O, Bormans G, Maes F, Himmelreich U, Nguyen H, Van Laere K (2011) Metabolic and type 1 cannabinoid receptor imaging of a transgenic rat model in the early phase of Huntington disease. Exp Neurol 229:440–449PubMedCrossRefGoogle Scholar
  107. 107.
    Kandasamy M, Couillard-Despres S, Raber KA, Stephan M, Lehner B, Winner B, Kohl Z, Rivera FJ, Nguyen HP, Riess O, Bogdahn U, Winkler J, von Horsten S, Aigner L (2010) Stem cell quiescence in the hippocampal neurogenic niche is associated with elevated transforming growth factor-beta signaling in an animal model of Huntington disease. J Neuropathol Exp Neurol 69:717–728PubMedCrossRefGoogle Scholar
  108. 108.
    Cao C, Temel Y, Blokland A, Ozen H, Steinbusch HW, Vlamings R, Nguyen HP, von Horsten S, Schmitz C, Visser-Vandewalle V (2006) Progressive deterioration of reaction time performance and choreiform symptoms in a new Huntington’s disease transgenic ratmodel. Behav Brain Res 170:257–261PubMedCrossRefGoogle Scholar
  109. 109.
    Urbach YK, Raber KA, Canneva F, Plank AC, Andreasson T, Ponten H, Kullingsjo J, Nguyen HP, Riess O, von Horsten S (2014) Automated phenotyping and advanced data mining exemplified in rats transgenic for Huntington’s disease. J Neurosci Methods 234:38–53PubMedCrossRefGoogle Scholar
  110. 110.
    Zeef DH, van Goethem NP, Vlamings R, Schaper F, Jahanshahi A, Hescham S, von Horsten S, Prickaerts J, Temel Y (2012) Memory deficits in the transgenic rat model of Huntington’s disease. Behav Brain Res 227:194–198PubMedCrossRefGoogle Scholar
  111. 111.
    Yu-Taeger L, Petrasch-Parwez E, Osmand AP, Redensek A, Metzger S, Clemens LE, Park L, Howland D, Calaminus C, Gu X, Pichler B, Yang XW, Riess O, Nguyen HP (2012) A novel BACHD transgenic rat exhibits characteristic neuropathological features of Huntington disease. J Neurosci 32:15426–15438PubMedCrossRefGoogle Scholar
  112. 112.
    Adjeroud N, Yague S, Yu-Taeger L, Bozon B, Leblanc-Veyrac P, Riess O, Allain P, Nguyen HP, Doyere V, El Massioui N (2015) Reduced impact of emotion on choice behavior in presymptomatic BACHD rats, a transgenic rodent model for Huntington Disease. Neurobiol Learn Mem 125:249–257PubMedCrossRefGoogle Scholar
  113. 113.
    Clemens LE, Weber JJ, Wlodkowski TT, Yu-Taeger L, Michaud M, Calaminus C, Eckert SH, Gaca J, Weiss A, Magg JC, Jansson EK, Eckert GP, Pichler BJ, Bordet T, Pruss RM, Riess O, Nguyen HP (2015) Olesoxime suppresses calpain activation and mutant huntingtin fragmentation in the BACHD rat. Brain 138:3632–3653PubMedCrossRefGoogle Scholar
  114. 114.
    Clemensson EK, Clemensson LE, Riess O, Nguyen HP (2017) The BACHD Rat model of huntington disease shows signs of fronto-striatal dysfunction in two operant conditioning tests of short-term memory. PLoS ONE 12:e0169051PubMedPubMedCentralCrossRefGoogle Scholar
  115. 115.
    El Massioui N, Lamirault C, Yague S, Adjeroud N, Garces D, Maillard A, Tallot L, Yu-Taeger L, Riess O, Allain P, Nguyen HP, von Horsten S, Doyere V (2016) Impaired Decision making and loss of inhibitory-control in a rat model of Huntington disease. Front Behav Neurosci 10:204PubMedPubMedCentralCrossRefGoogle Scholar
  116. 116.
    Lamirault C, Yu-Taeger L, Doyere V, Riess O, Nguyen HP, El Massioui N (2017) Altered reactivity of central amygdala to GABAAR antagonist in the BACHD rat model of Huntington disease. Neuropharmacology 123:136–147PubMedCrossRefGoogle Scholar
  117. 117.
    Manfre G, Doyere V, Bossi S, Riess O, Nguyen HP, El Massioui N (2016) Impulsivity trait in the early symptomatic BACHD transgenic rat model of Huntington disease. Behav Brain Res 299:6–10PubMedCrossRefGoogle Scholar
  118. 118.
    Weber JJ, Ortiz Rios MM, Riess O, Clemens LE, Nguyen HP (2016) The calpain-suppressing effects of olesoxime in Huntington’s disease. Rare Dis 4:e1153778PubMedPubMedCentralCrossRefGoogle Scholar
  119. 119.
    Yu-Taeger L, Bonin M, Stricker-Shaver J, Riess O, Nguyen HH (2017) Dysregulation of gene expression in the striatum of BACHD rats expressing full-length mutant huntingtin and associated abnormalities on molecular and protein levels. Neuropharmacology 117:260–272PubMedCrossRefGoogle Scholar
  120. 120.
    Nagy D, Tingley FD 3rd, Stoiljkovic M, Hajos M (2015) Application of neurophysiological biomarkers for Huntington’s disease: evaluating a phosphodiesterase 9A inhibitor. Exp Neurol 263:122–131PubMedCrossRefGoogle Scholar
  121. 121.
    Abada YS, Nguyen HP, Schreiber R, Ellenbroek B (2013) Assessment of motor function, sensory motor gating and recognition memory in a novel BACHD transgenic rat model for huntington disease. PLoS ONE 8:e68584PubMedPubMedCentralCrossRefGoogle Scholar
  122. 122.
    Abada YS, Nguyen HP, Ellenbroek B, Schreiber R (2013) Reversal learning and associative memory impairments in a BACHD rat model for Huntington disease. PLoS ONE 8:e71633PubMedPubMedCentralCrossRefGoogle Scholar
  123. 123.
    Jansson EK, Clemens LE, Riess O, Nguyen HP (2014) Reduced motivation in the BACHD rat model of Huntington disease is dependent on the choice of food deprivation strategy. PLoS ONE 9:e105662PubMedPubMedCentralCrossRefGoogle Scholar
  124. 124.
    Gouarne C, Tardif G, Tracz J, Latyszenok V, Michaud M, Clemens LE, Yu-Taeger L, Nguyen HP, Bordet T, Pruss RM (2013) Early deficits in glycolysis are specific to striatal neurons from a rat model of huntington disease. PLoS ONE 8:e81528PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  • J. Stricker-Shaver
    • 1
  • A. Novati
    • 1
  • L. Yu-Taeger
    • 1
  • H. P. Nguyen
    • 1
  1. 1.Institute of Medical Genetics and Applied GenomicsUniversity of TuebingenTuebingenGermany

Personalised recommendations